Immune Subtyping Identifies a Subset of HR+HER2- Early-Stage Breast Cancer Patients with a Very High Likelihood of Response to Neoadjuvant Immunotherapy (IO): Results from 5 IO Arms of the I-SPY2 TRIALDenise M. Wolf,Christina Yau,Lajos Pusztai,Rita Nanda,Jo Chien,Erica Stringer-Reasor,Rebecca Shatsky,Claudine Isaacs,MInetta Liu,Hyo Han,Hatem Soliman,Michael Campbell,Annuska Glas,Andrei Barcaru,Lorenza Mittempergher,Midas Kuilman,Lamorna Brown Swigart,Gillian Hirst,Hongmei Yu,Philip Beineke,Amrita Basu,Douglas Yee,W. Fraser Symmans,Angela DeMichele,Jane Perlmutter,Amy Delson,Laura Huppert,Hope Rugo,Amy Clark,Nola Hylton,Paula Pohlmann,Laura Esserman,Laura van 't VeerCancer Research（2024）Cited 0|Views51AI Read ScienceMust-Reading TreeExampleGenerate MRT to find the research sequence of this paperChat PaperSummary is being generated by the instructions you defined
